Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
RS Taylor - CMAJ, 2021 - Can Med Assoc
Across Canada, both influenza and respira tory syncytial virus (RSV) have been almost
completely absent during the 2020/21 win ter. 1 Data from the Southern hemisphere showed …
completely absent during the 2020/21 win ter. 1 Data from the Southern hemisphere showed …
Which should we fear more in preschoolers and infants: SARS-CoV-2 or respiratory syncytial virus?
V Coutinho Baldoto Gava Chakr - Postgraduate medical journal, 2022 - academic.oup.com
In late December 2019, the first pneumonia cases caused by the novel SARS-CoV-2 were
identified in Wuhan, China. 1 Initially, epidemiological data and clinical characteristics of …
identified in Wuhan, China. 1 Initially, epidemiological data and clinical characteristics of …
[HTML][HTML] Saudi experts' recommendation for RSV prophylaxis in the era of COVID-19: Consensus from the Saudi Pediatric Pulmonology Association
AS Alharbi, M Alzahrani, AN Alodayani… - Saudi Medical …, 2021 - ncbi.nlm.nih.gov
Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and viral
pneumonia in pediatrics worldwide. In the Kingdom of Saudi Arabia (KSA), the prevalence of …
pneumonia in pediatrics worldwide. In the Kingdom of Saudi Arabia (KSA), the prevalence of …
[HTML][HTML] Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia
F Al Aql, S Al-Hajjar, LB Mahmoud, S Al-Alaiyan… - International Journal of …, 2016 - Elsevier
Respiratory syncytial virus (RSV) is a leading cause of serious seasonal lower respiratory
tract infections (LRTI) in high-risk infants and children, with epidemics occurring annually in …
tract infections (LRTI) in high-risk infants and children, with epidemics occurring annually in …
[HTML][HTML] RSV immunisation: lessons from the COVID-19 pandemic
MN Billard, L Bont - The Lancet Child & Adolescent Health, 2023 - thelancet.com
Respiratory syncytial virus (RSV) is a major cause of hospital admissions in young children,
with the highest burden in infants younger than 3 months. A birth cohort study done in five …
with the highest burden in infants younger than 3 months. A birth cohort study done in five …
[HTML][HTML] Respiratory syncytial virus: promising progress against a leading cause of pneumonia
AS Ginsburg, P Srikantiah - The Lancet Global Health, 2021 - thelancet.com
This World Pneumonia Day, as the global COVID-19 pandemic persists, another deadly and
familiar, although under-recognised, respiratory virus requires attention: respiratory syncytial …
familiar, although under-recognised, respiratory virus requires attention: respiratory syncytial …
The impact of the COVID-19 pandemic on respiratory syncytial virus infection: a narrative review
YC Chuang, KP Lin, LA Wang, TK Yeh… - Infection and Drug …, 2023 - Taylor & Francis
Respiratory syncytial virus (RSV) is one of the most common respiratory viruses. It not only
affects young children but also the elderly and immunocompromised patients. After the …
affects young children but also the elderly and immunocompromised patients. After the …
[HTML][HTML] Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
B Paes, I Mitchell, A Li, KL Lanctôt - European journal of pediatrics, 2012 - Springer
Palivizumab utilization, compliance, and outcomes were examined in infants with
preexisting medical diseases within the Canadian Registry Database (CARESS) to aid in …
preexisting medical diseases within the Canadian Registry Database (CARESS) to aid in …
Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections
S Jun, M Sebastianski, R Featherstone, J Robinson - BMJ open, 2019 - bmjopen.bmj.com
Introduction Childhood respiratory syncytial virus (RSV) infection is a global phenomenon
that can lead to fatal respiratory illness. Palivizumab is a drug that is routinely used in …
that can lead to fatal respiratory illness. Palivizumab is a drug that is routinely used in …
Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection
MT Caserta, ST O'Leary, FM Munoz, SL Ralston - Pediatrics, 2023 - publications.aap.org
Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …